Low-dose rituximab protocol in rheumatoid arthritis-outcome and economic impact.
Parvathypriya ChandramohanRamnath MisraGlindow AntonyNarayanan KrishnanPadmanabha ShenoyPublished in: Rheumatology advances in practice (2021)
A low-dose RTX regimen achieved reasonably good clinical outcomes at the end of 6 months, with a significantly lower cost.